NGL FINECHEM
|
The Current P/S Ratio of NGL FINECHEM is 2.02.
| Share Price | ₹1,328.6 | Nov 25,2025 |
| Market Cap | ₹823.7 Cr | |
| Sales-TTM | ₹408.5 Cr | TTM-Consolidated Results |
| Price/Sales | 2.02x | Calculated as Market Cap/Sales |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PS (Price/Sales) ratio of NGL FINECHEM
P/S =
Market Capitalization
/
Sales
or, using per-share numbers:
P/S = Stock Price / Sales Per Share
Current Market Cap [ ₹823.7 Cr] as on Nov 25,2025
(/) Sales [ ₹408.5 Cr] based on TTM-Consolidated Results
(=) P/S Ratio [ 2.02x ]
Thus, for NGL FINECHEM , the investors are currently willing to pay '2.02 times sales' to own 1 share of the company.
PS Multiples are one of the most widely used valuation multiple in the industry.
P/S ratios can be a reliable benchmark to compare companies with negative earnings or book value.
You may also explore Price to Earnings ratio or Price to Book ratio of NGL FINECHEM !
The chart below summarizes the trend in P/S Ratio of NGL FINECHEM over the last five years.
Historical PS (Price/Sales) ratio chart of NGL FINECHEM
PS Ratio Performance Analysis for NGL FINECHEM
- NGL FINECHEM 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 3.16x.
- NGL FINECHEM 's operated at median p/e ratio of 3.67x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NGL FINECHEM 's p/e ratio peaked in Mar2024 at 3.81x.
- NGL FINECHEM 's p/e ratio hit its five-year low in Mar2025 of 1.87x.
How does NGL FINECHEM 's P/S Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Sales (Cr) | PS Ratio | Market Cap (Cr) |
|---|---|---|---|
| NGL FINECHEM | 408.5 | 2.02 | 823.7 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 54,964.0 | 7.73 | 425,102.0 |
| DIVIS LABORATORIES LTD | 10,029.0 | 16.98 | 170,299.0 |
| CIPLA LTD | 28,349.6 | 4.29 | 121,735.0 |
| TORRENT PHARMACEUTICALS LTD | 12,248.0 | 10.35 | 126,753.0 |
| DR REDDYS LABORATORIES LTD | 34,310.0 | 3.01 | 103,155.0 |
| MANKIND PHARMA LTD | 13,576.9 | 6.82 | 92,592.0 |
| ZYDUS LIFESCIENCES LTD | 24,493.9 | 3.81 | 93,328.2 |
| LUPIN LTD | 24,750.7 | 3.77 | 93,364.5 |
| AUROBINDO PHARMA LTD | 32,514.5 | 2.16 | 70,131.8 |
| ABBOTT INDIA LTD | 6,714.4 | 9.58 | 64,331.9 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PS Analysis vs NGL FINECHEM 's P/S Ratio
| Top 10 Industry Peers | PS Ratio |
|---|---|
| Min industry PS | 2.02x |
| Max industry PS | 16.98x |
| Median industry PS | 4.29x |
| Average industry PS | 6.41x |
You may also like the below Video Courses